ArticlePloS one2011
Difluoromethylornithine is a novel inhibitor of Helicobacter pylori growth, CagA translocation, and interleukin-8 induction.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.Cancer prevention research (Philadelphia, Pa.) · 2012Trial
- Review
- Article
- Reduction of UreB and CagA expression level by siRNA construct in Helicobacter pylori strain SS1.BMC microbiology · 2023Article
- Pd-Catalyzed Difluoromethylations of Aryl Boronic Acids, Halides, and Pseudohalides with ICFChemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Targeting Cytotoxin-Associated Antigen A, a Virulent Factor ofMolecules (Basel, Switzerland) · 2022Article
- One stomach, two subtypes of carcinoma-the differences between distal and proximal gastric cancer.Gastroenterology report · 2021Review
- The role of polyamines in gastric cancer.Oncogene · 2021Review
- Chemoprevention Against Gastric Cancer.Gastrointestinal endoscopy clinics of North America · 2021Review
- Curcumin Oxidation Is Required for Inhibition ofFrontiers in cellular and infection microbiology · 2021Article
- Transformation ofPathogens (Basel, Switzerland) · 2020Review
- Safety and efficacy of hydroxyurea and eflornithine against most blood parasites Babesia and Theileria.PloS one · 2020Article
- Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori Infection.Oncology (Williston Park, N.Y.) · 2019Article
- α-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations inProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- The Immune Battle against Helicobacter pylori Infection: NO Offense.Trends in microbiology · 2016Review
- Galectin-3 Plays an Important Role in Innate Immunity to Gastric Infection by Helicobacter pylori.Infection and immunity · 2016Article
- At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer.Journal of leukocyte biology · 2014Review
- Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy.Amino acids · 2014Article
- Gut microbes, diet, and cancer.Cancer treatment and research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Helicobacter pylori infects half the world's population, and carriage is lifelong without antibiotic therapy. Current regimens prescribed to prevent infection-associated diseases such as gastroduodenal ulcers and gastric cancer can be thwarted by antibiotic resistance. We reported that administration of 1% D,L-α-difluoromethylornithine (DFMO) to mice infected with H. pylori reduces gastritis and colonization, which we attributed to enhanced host immune response due to inhibition of macrophage ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Although no ODC has been identified in any H. pylori genome, we sought to determine if DFMO has direct effects on the bacterium. We found that DFMO significantly reduced the growth rate of H. pylori in a polyamine-independent manner. Two other gram-negative pathogens possessing ODC, Escherichia coli and Citrobacter rodentium, were resistant to the DFMO effect. The effect of DFMO on H. pylori required continuous exposure to the drug and was reversible when removed, with recovery of growth rate in vitro and the ability to colonize mice. H. pylori exposed to DFMO were significantly shorter in length than those untreated and they contained greater internal levels of ATP, suggesting severe effects on bacterial metabolism. DFMO inhibited expression of the H. pylori virulence factor cytotoxin associated gene A, and its translocation and phosphorylation in gastric epithelial cells, which was associated with a reduction in interleukin-8 expression. These findings suggest that DFMO has effects on H. pylori that may contribute to its effectiveness in reducing gastritis and colonization and may be a useful addition to anti-H. pylori therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.